Here for you, every second

Locations

United Kingdom
Kiniksa Pharmaceuticals (UK), Ltd.
Third Floor
23 Old Bond Street
London, UK
W1S 4PZ
US Headquarters
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA 02421 USA
(781) 431-9100
USA California
Kiniksa Pharmaceuticals Corp.
9191 Towne Centre Drive, Suite 330
San Diego, CA 92122
Bermuda
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM 11

Utility

Contact Us

Main navigation

About Us
Medicines & Pipeline
Patients & Advocacy
- Diseases
Investors
Join Us

Menu

IR navigation

News & Events
Stock Information
- Stock Quote & Chart
- Historical Price Lookup
Financial Information
Corporate Governance
Investor Resources

Press Releases

Year

All
2023
2022
2021

12/28/21

Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
11/23/21

Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference
11/01/21

Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution
10/29/21

Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021
09/21/21

Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
08/16/21

Kiniksa Announces Launch of ARCALYST Named Patient Program
08/03/21

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
08/02/21

Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
07/20/21

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
06/08/21

Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
06/08/21

Kiniksa Outlines Next Steps for the Development of Mavrilimumab
06/01/21

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
05/04/21

Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
05/04/21

Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
04/12/21

Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
04/01/21

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
03/18/21

Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
03/02/21

Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
02/23/21

Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
01/11/21

Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones
01/04/21

Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Print Page

RSS

Email Alerts

Search

Image

United Kingdom
Kiniksa Pharmaceuticals (UK), Ltd.
Third Floor
23 Old Bond Street
London, UK
W1S 4PZ
US Headquarters
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA 02421 USA
(781) 431-9100
USA California
Kiniksa Pharmaceuticals Corp.
9191 Towne Centre Drive, Suite 330
San Diego, CA 92122
Bermuda
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM 11